



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at [www.bccancer.bc.ca](http://www.bccancer.bc.ca) and according to acceptable standards of care

**PROTOCOL CODE: LYGEMOXPEG**

(Page 1 of 3)

<b>DOCTOR'S ORDERS</b>	Ht _____ cm	Wt _____ kg	BSA _____ m <sup>2</sup>
<b>REMINDER:</b> Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form			
<b>DATE:</b>	<b>To be given:</b>	<b>Cycle #:</b>	
Date of Previous Cycle:			
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> <b>CBC &amp; Diff and platelets</b> day 1 of treatment Day 1: May proceed with doses as written, if within 72 hours <b>ANC greater than or equal to 1.0 x 10<sup>9</sup>/L, Platelets greater than or equal to 75 x 10<sup>9</sup>/L, creatinine clearance greater than or equal to 50 mL/minute, direct bilirubin less than 51 micromol/L, ALT less than or equal to 5 times upper limit of normal</b> Day 8: May proceed with doses as written, if within 48 hours <b>ANC greater than or equal to 1.0 x 10<sup>9</sup>/L, Platelets greater than or equal to 75 x 10<sup>9</sup>/L</b> Dose modification for: <input type="checkbox"/> <b>Hematology</b> <input type="checkbox"/> <b>Other Toxicity</b> _____ <b>Proceed with treatment based on blood work from</b> _____			
<b>PREMEDICATIONS:</b> Patient to take own supply. RN/Pharmacist to confirm _____.			
<u><b>DAY 1</b></u>			
ondansetron 8 mg PO prior to treatment.			
dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg PO (select one) prior to treatment.			
<input type="checkbox"/> Other:			
<u><b>Prior to pegaspargase:</b></u>			
acetaminophen 650 mg PO			
diphenhydrAMINE <input type="checkbox"/> 25 mg or <input type="checkbox"/> 50 mg (select one) <input type="checkbox"/> PO or <input type="checkbox"/> IV (select one)			
hydrocortisone 100 mg IV			
If fibrinogen less than 0.5 g/L:			
<input type="checkbox"/> <b>fibrinogen concentrate 4 g</b> IV prior to pegaspargase (complete transfusion medicine order).			
Refer to protocol for guidance regarding pegaspargase.			
<b>NO ice chips.</b>			
<u><b>DAY 8</b></u>			
<input type="checkbox"/> prochlorperazine 10mg PO or <input type="checkbox"/> metoclopramide 10mg PO prior to treatment			
<input type="checkbox"/> Other			
<b>DOCTOR'S SIGNATURE:</b>			<b>SIGNATURE:</b>
			<b>UC:</b>



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at [www.bccancer.bc.ca](http://www.bccancer.bc.ca) and according to acceptable standards of care

**PROTOCOL CODE: LYGEMOXPEG**

(Page 2 of 3)

**Date:**

**\*\* Have Hypersensitivity Reaction Tray and Protocol Available\*\***

**TREATMENT:**

**CHEMOTHERAPY**

**gemcitabine 1000 mg/m<sup>2</sup> x BSA = \_\_\_\_\_ mg**

Dose Modification: \_\_\_\_\_% = \_\_\_\_\_ mg/m<sup>2</sup> x BSA = \_\_\_\_\_ mg

IV in 250 mL NS over 30 minutes on **Day 1 and Day 8**

**oxaliplatin 130 mg/m<sup>2</sup> x BSA = \_\_\_\_\_ mg**

Dose Modification: \_\_\_\_\_mg/m<sup>2</sup> x BSA = \_\_\_\_\_mg

IV in 250 to 500 mL D5W over 2 hours. Flush line with D5W pre and post oxaliplatin on **Day 1**

RN to administer 250 to 1000 mL D5W concurrently with oxaliplatin infusion, titrated to reduce phlebitis discomfort for patient

**pegaspargase**  **2500 units/m<sup>2</sup>** or  **1500 units/m<sup>2</sup>** (select one) X BSA = \_\_\_\_\_ units

IV in 100 mL NS over 1 hour **OR**  IM (select one) on **Day 1**

Dose Modification: \_\_\_\_\_ units/m<sup>2</sup> x BSA x \_\_\_\_\_% = \_\_\_\_\_ units

IV in 100 mL NS over 1 hour **OR**  IM (select one) on **Day 1**

**Note:** for IM administration: volumes greater than 2 mL should be administered in 2 separate sites to reduce pain

For IV infusion: Monitor BP and vitals before and at 15, 30 and 60 minutes during pegaspargase administration; observe for 1 hour after end of infusion

For IM injection: Monitor BP and vitals, plus visual inspection of injection site before and after injection; and observe for 1 hour after injection

**DOSE MODIFICATION (IF REQUIRED) ON DAY 8:**

**gemcitabine 1000 mg/m<sup>2</sup> x BSA = \_\_\_\_\_ mg**

Dose Modification: \_\_\_\_\_% = \_\_\_\_\_ mg/m<sup>2</sup> x BSA = \_\_\_\_\_ mg

IV in 250 mL NS over 30 minutes on **Day 8**

**DOCTOR'S SIGNATURE:**

**SIGNATURE:**

**UC:**



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at [www.bccancer.bc.ca](http://www.bccancer.bc.ca) and according to acceptable standards of care

**PROTOCOL CODE: LYGEMOXPEG**

(Page 3 of 3)

<b>Date:</b>	
<b>RETURN APPOINTMENT ORDERS</b>	
<input type="checkbox"/> Return in <b>three</b> weeks for Doctor and Cycle _____. Book chemo on Day 1 and Day 8. <input type="checkbox"/> Last Cycle. Return in _____ week(s).	
<p><b>CBC and differential, platelets, creatinine, sodium, potassium, magnesium, calcium, phosphate, albumin, bilirubin (direct and indirect), ALT, alkaline phosphatase, GGT, LDH, triglycerides, lipase, random glucose, uric acid, INR, PT, PTT, fibrinogen</b> prior to Day 1</p> <p><b>CBC and differential, platelets</b> prior to Day 8</p> <p><b>ALT, alkaline phosphatase, GGT, bilirubin (direct and indirect), lipase, random glucose</b> twice a week (every Monday and Thursday)</p> <p><input type="checkbox"/> If clinically indicated: <b>EBV DNA</b></p> <p><input type="checkbox"/> <b>ECG</b></p> <p><input type="checkbox"/> <b>Other tests:</b></p> <p><input type="checkbox"/> <b>Consults:</b></p> <p><input type="checkbox"/> See general orders sheet for additional requests.</p>	
<b>DOCTOR'S SIGNATURE:</b>	<b>SIGNATURE:</b>
	<b>UC:</b>